Drug & Medical Device Litigation 2011

Be a Part of the 16th Annual Event that Shapes the Industry

Every December for the past 15 years, leading drug and medical device lawyers have gathered in New York to shareoutstanding networking and learning opportunities, and to craft strategies for meeting new litigation challenges. Thisevent is the premier industry showcase for hearing expert insights unavailable in any other forum, and for meeting the people that will shape the response to lawsuits in the year to come. ACI’S DRUG AND MEDICAL DEVICE LITIGATION is the very finest opportunity for lawyers all across the U.S. to meet one another and to benchmark their current products liability defense strategies.

As a special feature, this year’s DRUG AND MEDICAL DEVICE LITIGATION will again include exciting group “meet-ups” that kick off the program with unparalleled networking and learning opportunities. As you meet new colleagues and consider the issues raised in dynamic hypotheticals with the help of in-house counsel facilitators, you will immediately begin to reap the benefits of this premiere program. In addition, as we focus on complex multidistrict litigation the judicial panel will include six leaders from the federal bench with distinguished records of industry mass torts oversight, and we will hear spotlight remarks from Professor Francis McGovern, the nation’s leading expert on the settlement of mass torts cases. We will also be honored to hear in-house insights from many new speakers with responsibility for managing the litigation dockets for their companies’ business units, including Malini Moorthy, Assistant General Counsel - Litigation for Pfizer and Adam Deutsch, Vice President and Associate General Counsel, Litigation for Biomet.

NEW THIS YEAR

• Ethics Workshop: Practical and Ethical Tools for Successful Mass Tort Litigation, will provide an opportunity for practitioners to learn insider strategies from seasoned litigators and be ready to take their practice to the next level
• The Business Development Master Class: In-House Perspectives on Selection and Evaluation of Outside Counsel will present a rare and candid view of the inner thought processes of in-house counsel.

This year’s 16th Annual conference, featuring a stellar faculty of industry leaders, will provide you with the information and tools you need to successfully overcome new and changing threats. Our faculty of over 25 in-house counsel from leading pharmaceutical and device companies and renowned litigators will share the methods that have worked for them in recent battles, and provide specifi c advice for both defeating claims and for litigating effi ciently and costeffectively. Particular areas of focus will include:

• Applying new tactics to reject “economic loss” claims
• Devising the most effective strategy for juggling civil litigation and criminal concerns
• Overcoming presumptions against preemption defenses in light of Mensing
• Developing post-recall evidentiary and trial strategies
• Managing MDL coordination challenges and maneuvering for desirable forums and case sequences
• Ensuring that the judge and jury will understand the complex science underlying your case

New York City, with its vibrant cultural resources, has been the home for the DRUG AND MEDICAL DEVICE LITIGATION program since its inception and provides many excellent networking opportunities for the over 500 drug and medical device industry professionals attending the conference.

Register early to reserve your place for this important industry event and lock in the best rate. Call 1-888-224-2480; fax your registration to 1-877-927-1563; or register online

Topics to be addressed at the 2011 Drug & Medical Device Litigation conference include:

• Employing strategies that are proving effective in recent MDL litigation
• Revamping trial tactics to account for the explosion in use of social media
• Assessing when and how to introduce FDA evidence
• Selecting neutral jurors and preventing bias
• Meeting client expectations and their criteria for selecting and working with outside counsel
• Formulating defenses for the increasing number of claims that reference both brand and generic products
• Minimizing the negative impact of drug and device recalls
• Defending cases in high-risk jurisdictions

The 2011 conference will feature faculty from these industry leaders:

• Abbott
• Actavis
• Actelion
• Allergan Inc.
• AstraZeneca
• Bayer
• Biomet Inc.
• Boehinger Ingelheim
• ConvaTec
• C.R. Bard
• Eli Lilly and Company
• Ferring
• GE Healthcare
• Gilead
• GlaxoSmithKline
• Medtronic
• Merck
• Pfizer Inc.
• Purdue Pharma L.P.
• Sandoz
• Stryker
• Taro
• Teva